Fiche publication
Date publication
décembre 2014
Auteurs
Membres identifiés du Cancéropôle Est :
Pr AUBIN François
,
Pr GARNACHE-OTTOU Francine
,
Pr HUMBERT Philippe
Tous les auteurs :
Pelletier F, Garnache-Ottou F, Biichle S, Vivot A, Humbert P, Saas P, Seilles E, Aubin F
Lien Pubmed
Résumé
Psoriasis involves TNF-alpha secretion leading to release of microparticles into the bloodstream. We investigated the effect of TNF blockers on microparticles levels before and after treatment in patients (twenty treated by anti-TNF-alpha agents and 6 by methotrexate) with severe psoriasis. Plasmatic microparticles were labelled using fluorescent monoclonal antibodies and were analysed using cytometry. Three months later, 70% of patients treated with anti-TNF-alpha agents achieved a reduction in PASI score of at least 75%. The clinical improvement in patients treated with anti-TNF-alpha agents was associated with a significant reduction of the mean number of platelet microparticles (2837/mul vs 1849/mul, P = 0.02) and of endothelial microparticles (64/mul vs 22/mul, P = 0.001). Microparticles are significantly decreased in psoriatic patients successfully treated by anti-TNF-alpha. Microparticles levels as circulating endothelial cells represent signs of endothelial dysfunction and are elevated in psoriasis. Then, TNF blockade may be effective to reduce cardiovascular risk through the reduction of circulating microparticles.
Référence
Exp Dermatol. 2014 Dec;23(12):924-5
